What Is Exenatide?
Exenatide is the original GLP-1 receptor agonist, derived from a compound found in the saliva of the Gila monster lizard. It is manufactured by AstraZeneca and sold under two brand names: Byetta (twice-daily injection) and Bydureon (once-weekly extended-release injection). Byetta was FDA-approved in April 2005 — making it the first GLP-1 medication ever approved, more than a decade before Wegovy and Zepbound transformed the obesity treatment landscape.
Byetta vs. Bydureon
Byetta is an immediate-release formulation injected twice daily within 60 minutes before morning and evening meals. Bydureon is an extended-release formulation injected once weekly. Bydureon generally produces more stable drug levels and is more convenient, though both forms are less commonly prescribed today given the superior efficacy of newer agents.
Why Exenatide Matters Historically
Exenatide proved the concept. It demonstrated that a GLP-1 receptor agonist could meaningfully lower blood sugar, produce weight loss as a secondary benefit, and be tolerated in a broad patient population. The clinical learnings from exenatide directly informed the development of liraglutide, semaglutide, and tirzepatide.
When Exenatide Might Still Be Prescribed
Exenatide is typically prescribed today when cost is the primary constraint and newer agents are not covered, when a patient has previously tolerated it well, or in healthcare systems with different formulary structures. Generic versions are available in some markets, significantly reducing cost.